What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market

What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress in diagnostic devices, development and endorsement of drugs, patient advocacy and assistance, and collaborative research efforts.

In the coming years, the transthyretin amyloidosis treatment market is projected to experience significant growth. It is anticipated to reach a value of $8.04 billion in 2029, reflecting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period could be the result of an expanded therapy pipeline, increased genetic screenings, global initiatives for the awareness of rare diseases, personalized medicinal methods, and improved treatment accessibility. Key trends for the forecast period incorporate the inception of combination therapies, alliances for drug development, focus on targeting peripheral and cardiac symptoms, the execution of patient education schemes, and inclusion of real-world evidence in treatment standards.

What Are the Main Catalysts for Growth in the Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market is projected to grow due to heightened investments in research and development activities. These investments are typically geared towards scientific advancements, innovative technology development, novel product creation, and process improvement. Greater financial infusion into R&D paves the way for the discovery and advancement of new treatment methods for transthyretin amyloidosis, which can range from cutting-edge drug therapy to precision medicine techniques. These new treatments offer sufferers better and more personalized care. For example, Alnylam Pharmaceuticals, a US-based biopharmaceutical company working on Vutrisiran, a therapy for ATTR amyloidosis, enhanced its R&D funding to $883,015 in 2022, up from $792,156 in 2021, demonstrating growth of 11.49%. This surging commitment to R&D is expected to fuel the transthyretin amyloidosis treatment market. A significant driver in the growth of the transthyretin amyloidosis treatment market is the global trend towards an aging population. This demographic shift, characterized by declining fertility rates and increased life expectancy, leads to an increased median age amongst the populace. This aging phenomenon is a known risk factor for Transthyretin Amyloidosis. As such, as the population grows older, the frequency of Transthyretin Amyloidosis cases increase, creating a larger population in need of treatment. For instance, according to the World Health Organization in October 2022, every country is witnessing demographical shifts that result in an increased proportion of older individuals. They predict that by 2030, one-sixth of the global population will be aged 60 years or older, consequently driving the growth of the transthyretin amyloidosis treatment market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

Which Businesses Are at the Forefront of Transthyretin Amyloidosis Treatment Market Development?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

What Are the Latest Innovations in the Transthyretin Amyloidosis Treatment Market?
To enhance patient outcomes and broaden the range of treatment options, leading companies in the transthyretin amyloidosis treatment market are focusing on the development of innovative and specialized treatments, such as orphan drugs. Eplontersen, an example of an orphan drug, has been specifically tailored to address the transthyretin amyloidosis condition and has often been given regulatory incentives to aid in its development. Notably, in March 2023, The Food and Drug Administration (FDA) granted the approval of a new drug application for Eplontersen to Ionis Pharmaceuticals, Inc. This company, based in Canada, specialises in biotechnology research. The drug being developed, Eplontersen, is geared towards treating familial transthyretin-mediated amyloid that leads to advancing polyneuropathy. It is a pharmaceutical product designed to reduce the synthesis of transthyretin (TTR) protein, thereby addressing both hereditary and non-hereditary versions of ATTR amyloidosis, also known as amyloid transthyretin amyloidosis. The FDA provided Eplontersen with the orphan drug designation in 2022.

How Is the Transthyretin Amyloidosis Treatment Market Segmented?
The transthyretin amyloidosis treatment market covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Where Is the Transthyretin Amyloidosis Treatment Market Growth Most Prominent?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Is Covered In The Transthyretin Amyloidosis Treatment Global Market Report?

- Market Size Analysis: Analyze the Transthyretin Amyloidosis Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Transthyretin Amyloidosis Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Transthyretin Amyloidosis Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Transthyretin Amyloidosis Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.